IMPORTANT REMINDER

The Medicare Advantage Medical Policy manual is not intended to override the member Evidence of Coverage (EOC), which defines the insured's benefits, nor is it intended to
DESCRIPTION
Autologous islet transplantation is commonly conducted during pancreatectomy among patients with chronic pancreatitis. The procedure consists of isolating islet cells from the patient's resected pancreas using enzymes, and injecting a suspension of the cells back into the portal vein of the patient's liver, where the cells function as a free graft.
For patients with type 1 diabetes, allogeneic islet cell transplantation may be performed as a stand-alone procedure. Islet cells that have been harvested from a deceased donor's pancreas are processed and injected into the recipient's portal vein.
It is proposed that the beta cells in the transplanted islets will begin to make and release insulin. Therefore, one of the desired patient outcomes is insulin independence. 
MEDICARE ADVANTAGE POLICY
POLICY GUIDELINES REQUIRED DOCUMENTATION
The information below must be submitted for review to determine whether policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome:
• Medicare Explanation of Benefits (MEOB). [3] CMS has issued statement that Medicare or the Medicare contractor will make payment on behalf of Medicare Advantage Organizations (MAOs) for MA enrollees for these services. MAOs may process claims as secondary.
CROSS REFERENCES
Pancreas Transplants, Transplants, Policy No. M-06
